Patent: 9,441,037
✉ Email this page to a colleague
Summary for Patent: 9,441,037
Title: | Methods for reducing exacerbation rates of asthma using benralizumab |
Abstract: | Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof. |
Inventor(s): | Ward; Christine (Gaithersburg, MD), Roskos; Lorin (Gaithersburg, MD), Wang; Bing (Gaithersburg, MD), Raible; Donald (Berwyn, PA) |
Assignee: | ASTRAZENECA AB (Sodertalje, SE) |
Application Number: | 14/453,942 |
Patent Claims: | see list of patent claims |
Details for Patent 9,441,037
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Astrazeneca Ab | FASENRA | benralizumab | Injection | 761070 | 11/14/2017 | ⤷ Try a Trial | 2033-08-12 |
Astrazeneca Ab | FASENRA | benralizumab | Injection | 761070 | 10/03/2019 | ⤷ Try a Trial | 2033-08-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |